Katalin Bognar

Katalin Bognar

Auto-generated profile, based on publicly available information

Katalin Bognar

Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 90212, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Cancer Discovery
Verified
Journal Article
Open access
PMPeter Mazzone
Peter Mazzone
PBPeter B Bach
Peter B Bach
JCJacob Carey
Jacob Carey
CSCaitlin A. Schonewolf
Caitlin A. Schonewolf
KBKatalin Bognar
Katalin Bognar
LPLuke R.G. Pike
Luke R.G. Pike
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case–control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when positive is followed by a low-dose computed tomography. Changes in genome-wide cell-free DNA fragmentation profiles (fragmentomes) in peripheral blood reflected genomic and chromatin characteristics of lung cancer. We applied machine learning to fragmentome features to identify individuals who were more or less likely to have lung cancer. We trained the classifier using 576 cases and controls from study samples and validated it in a held-out group of 382 cases and controls. The validation demonstrated high sensitivity for lung cancer and consistency across demographic groups and comorbid conditions. Applying test performance to the screening eligible population in a 5-year model with modest utilization assumptions suggested the potential to prevent thousands of lung cancer deaths. Significance: Lung cancer screening has poor adoption. Our study describes the development and validation of a novel blood-based lung cancer screening test utilizing a highly affordable, low-coverage genome-wide sequencing platform to analyze cell-free DNA fragmentation patterns. The test could improve lung cancer screening rates leading to substantial public health benefits. See related commentary by Haber and Skates, p. 2025

1 October 2018 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
JSJason Shafrin
Jason Shafrin
KBKatalin Bognar
Katalin Bognar
KEKatie Everson
Katie Everson
MBMichelle Brauer
Michelle Brauer
DLDarius N Lakdawalla
Darius N Lakdawalla
FFFelicia M Forma
Felicia M Forma
Background: New digital technologies offer providers the promise of more accurately tracking patients’ medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world. Methods: Using prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers’ knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI). We examined patients who initiated an oral atypical antipsychotic, but were later objectively non-adherent to this treatment, defined as proportion of days covered (PDC) <0.8. We examined how a physician’s awareness of patient non-compliance (ICD-9 diagnosis code: V15.81) was correlated with the physician’s real-world treatment decisions for that patient. Treatment decisions studied included the share of patients who increased antipsychotic dose, augmented treatment, switched their antipsychotic, or used a long-acting injectable (LAI). Results: Among the 286,249 patients with SMI who initiated an antipsychotic and had PDC <0.8, 4,033 (1.4%) had documented non-compliance. When prescribers documented non-compliance, patients were more likely to be switched to another antipsychotic (32.8% vs 24.7%, P<0.001), have their dose increased (24.4% vs 22.1%, P=0.004), or receive an LAI (0.09% vs 0.04%, P=0.008), but were less likely to have augmented therapy with another antipsychotic (1.1% vs 1.3%, P=0.035) than patients without documented non-compliance. Conclusion: Among SMI patients with documented non-compliance, the frequency of dose, medication switches, and LAI use were higher and augmentation was lower compared to patients without documented non-compliance. Access to adherence information may help prescribers more rapidly switch ineffective medications as well as avoid unnecessary medication augmentation.

2 April 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
JOJesse D. Ortendahl
Jesse D. Ortendahl
GCGebra Cuyun Carter
Gebra Cuyun Carter
STSnehal G. Thakkar
Snehal G. Thakkar
KBKatalin Bognar
Katalin Bognar
DHDavid W. Hall
David W. Hall
YAYara Abdou
Yara Abdou
Aims: The availability of targeted therapies for oncology patients is increasing. Available genomic tests to identify treatment-eligible patients include single gene tests and gene panel tests, including the whole-exome, whole-transcriptome OncoExTraTM test. We assessed the costs and clinical benefits of test choice. Methods: A Microsoft Excel-based model was developed to evaluate test choice in patients with advanced/metastatic non-small cell lung cancer (NSCLC), breast, prostate, and colorectal cancer. Treatment pathways were based on NCCN guidelines and medical expert opinion. Inputs were derived from published literature. Annual economic results and lifetime clinical results with OncoExTra testing were projected per-tested-patient and compared with single gene testing and no testing. Separately, results were estimated for a US health plan without the OncoExTra test and with its use in 5% of patients. Results: Compared with no genomic testing, OncoExTra test use increased costs by $4,915 per patient; however, 82%-92% of individuals across tumor types were identified as eligible for targeted therapy or a clinical trial. Compared with single gene testing, OncoExTra test use decreased costs by $9,966 per-patient-tested while increasing use of approved or investigational targeted therapies by 20%. When considering a hypothetical health plan with 1 million members, 858 patients were eligible for genomic testing. Using the OncoExTra test in 5% of those eligible, per-member per-month costs decreased by $0.003, ranging from cost-savings of $0.026 in NSCLC patients to a $0.009 increase in prostate cancer patients. Cost-savings were driven by reduced treatment costs with increased clinical trial enrollment and reduced direct and indirect medical costs associated with targeted treatments. Conclusions: Limitations include the required simplifications in modeling complex conditions that may not fully reflect evolving real-world testing and treatment patterns. Compared to single-gene testing, results indicate that using NGS test such as OncoExTra identified more actionable alterations, leading to improved outcomes and reduced costs.

1 June 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
JOJesse D. Ortendahl
Jesse D. Ortendahl
GCGebra Cuyun Carter
Gebra Cuyun Carter
STSnehal G. Thakkar
Snehal G. Thakkar
KBKatalin Bognar
Katalin Bognar
DHDavid W. Hall
David W. Hall
DGDavid R. Gandara
David R. Gandara
PURPOSE: With an increase in approved targeted therapies for non–small cell lung cancer (NSCLC), tumor profiling that maximizes identification of patients eligible for these treatments is essential. In this study, we compare testing approaches for newly diagnosed advanced or metastatic NSCLC. METHODS: An economic model was developed to estimate the annual costs and clinical outcomes associated with testing alternatives. Patients were assigned alterations on the basis of rates observed in published literature. Treatment approaches included no genomic testing; sequential single-gene testing; or a whole-exome, whole-transcriptome (WES/WTS) comprehensive genomic profiling to inform use of targeted therapies. The budget impact and survival implications of WES/WTS were compared head to head with the other testing approaches, and uncertainty was assessed in sensitivity analyses. In scenario analyses, tests that incorporate both DNA and RNA were compared with tests using DNA sequencing alone when assuming the prevalence of fusions that can only be identified by RNA ranged from 2.5% to 14%. RESULTS: Compared with no testing, WES/WTS reduced costs by $8,809 in US dollars (USD) per patient tested while increasing median overall survival by an average of 3.9 months. When compared with sequential single-gene testing, use of WES/WTS decreased costs by $14,602 (USD) per patient and had a minimal survival benefit. A test that included both RNA and DNA sequencing reduced costs by $400-$1,724 (USD) and increased identification of actionable alterations by 2.3%-13.0% across the range of fusion prevalence. CONCLUSION: Use of WES/WTS improved clinical outcomes while reducing costs. These findings should be considered when choosing between tumor profiling approaches.

1 February 2023 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
TQTiffany P Quock
Tiffany P Quock
ADAnita D'SOuza
Anita D'SOuza
MBMichael S Broder
Michael S Broder
KBKatalin Bognar
Katalin Bognar
ECEunice Chang
Eunice Chang
MTMarian H Tarbox
Marian H Tarbox
Aim: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. Materials & methods: This retrospective analysis used nationally representative hospital discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizations among patients with AL amyloidosis. Results: Of 1341 patients identified, 92% were discharged alive and 8% experienced in-hospital death. Compared with the average US hospital stay during 2017–2019 (4.7 days, mean costs of $13,046 and mean charges of $54,496), hospital stays for AL amyloidosis were longer and costlier (9.7 days, $27,098.61, $111,233.91), especially in patients with in-hospital death (12.2 days, $44,966, $182,338.18). Conclusion: AL amyloidosis is associated with significant clinical and economic burden.

1 December 2022 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
ADAnita D’souza
Anita D’souza
MBMichael S Broder
Michael S Broder
KBKatalin Bognar
Katalin Bognar
ECEunice Chang
Eunice Chang
MTMarian H Tarbox
Marian H Tarbox
TQTiffany P Quock
Tiffany P Quock
Aim: Estimate the frequency and costs of diagnostic admissions among hospitalized patients with amyloid light chain (AL) amyloidosis. Materials & methods: This retrospective analysis used nationally representative hospital discharge data from 2017 to 2020 to report resource use and cost for hospitalizations during which AL amyloidosis was diagnosed. Results: Of 1341 admissions, 17.6% were diagnostic. Bone marrow (79.5%) and kidney (44.9%) biopsies were the most common qualifying biopsies. Diagnostic hospitalizations had longer length of stay (14.5 vs 8.4 days; p < 0.001) and higher cost ($40,052 [USD] vs $24,360; p < 0.001) than nondiagnostic ones. Conclusion: Diagnostic admissions are more likely to be urgent/emergent, require longer stays and have higher costs compared with hospitalizations in known AL amyloidosis patients. Improved diagnostic pathways toward early diagnosis are needed. Plain language summary What is this article about? Diagnosing amyloid light chain (AL) amyloidosis is challenging and may occur during an acute admission, which may be resource intensive and costly. The objective of the study was to estimate the frequency of diagnostic admissions among hospitalized patients with AL amyloidosis and the associated healthcare utilization and costs. What were the results? About 17.6% of hospital admissions for patients with AL amyloidosis were identified as a diagnostic encounter. Patients with AL amyloidosis diagnosed in the hospital have longer hospital stays and higher costs than other AL amyloidosis hospitalizations. What do the results of the study mean? Results suggest that continued effort is needed to improve diagnostic pathways toward early diagnosis of this multisystem disease.